Drugs

Apr 7, 2024, 11:58

Cathy Eng: Award for my contribution to The Lancet: FRESCO-2 and the FDA approval of fruquintinib

Cathy Eng shared on X/Twitter:

“This lovely keepsake arrived. I want to thank Vanderbilt University Medical Center and my colleagues for nominating me for the 2023 Biomedical Science Impact Award for my contribution to The Lancet: FRESCO-2 and the FDA approval of fruquintinib with Arvind Dasari.”

Source: Cathy Eng/X

Cathy Eng is a Professor of Medicine, Hematology and Oncology, and is the Co-Director of GI Oncology and Co-Leader of the Gastrointestinal Cancer Research Program at the Vanderbilt-Ingram Cancer Center. She also holds the David H. Johnson Endowed Chair of Surgical and Medical Oncology. Dr. Eng was previously a Professor of Medical Oncology at The University of Texas MD Anderson Cancer Center. Her primary clinical research interests include clinical trials involving innovative drugs for the treatment of colorectal, anal, and appendiceal cancers. She has a specific interest in young colorectal cancer patients as well as the role of immunotherapy in HPV-associated cancers. Nationally, Dr. Eng has served in multiple leadership roles for ASCO, ASCO GI, ECOG, and the NCI Rectal/Anal Task Force. She has most recently been chosen to serve as the Vice-Chair for the SWOG GI Committee and the NCI GI Steering Committee.

Arvind Dasari Biomedical Science Impact Award cancer Cathy Eng FDA FRESCO-2 Fruquintinib OncoDaily Oncology The Lancet Vanderbilt University Medical Center

Mark Ruffalo and Brain Cancer: How He Went Against, How He Survived, and More

Sharon Osbourne and Colon Cancer: How She Went Against, How She Survived, and More

Marcia Cross and Anal Cancer: How She Went Against, How She Survived, and More

Pancreatic Cancer: Symptoms, Causes, Types, Diagnosis & Treatment

FDA approves Methotrexate for Pediatric acute Lymphoblastic Leukemia

Special Coverage